Aclaris Therapeutics (ACRS) IPO Prices at $11, Well Below Expected Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Google escapes ad tech breakup in third Big Tech antitrust loss for US
Aclaris Therapeutics (ACRS) IPO Opens 9% Higher
October 7, 2015 10:07 AM EDTToday's IPO for Aclaris Therapeutics (NASDAQ: ACRS) opened for trading at $11.94 after pricing 5,000,000 shares of its common stock at a price to the public of $11.00 per share, below the expected $14-$16 range.
Jefferies LLC and Citigroup Global Markets Inc. are acting as joint... More
